 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summary
Celldex Therapeutics
CLDX
conference date: February 14, 2017 @ 1:30 PM Pacific Time
for quarter ending: December 31, 2017 (Q4, fourth quarter 2016)
Overview: A clinical stage biotechnology company reports progress on its many pipeline projects.
Basic data (GAAP):
Revenue was $ million, up sequentially from $1.4 million but down from $ million year-earlier. All revenue was from license agreements, contract or grants.
Net loss was $ million, up sequentially from $32.0 million and up from a net loss of $ million year-earlier.
EPS was negative $, up sequentially from negative $0.32, and up from negative $ year-earlier.
Guidance:
none
Conference Highlights:
CEO Anthony Marucci stated "
A Phase 1/2 study of CDX-014 (glembatumumab vedotin), an ADC targeting TIM-1, for renal cell carcinoma
Celldex is working with Bristol-Myers to do a broad Phase 1/ 2 combination study of varlilumab (CDX-1127) with nivolumab (Opdivo).
CDZ-1127 is in a combined with Tecetriq
A Phase 1/2 study of varlilumab with atezolizumab (anti-PDL1) is enrolling; Phase 2 will be for renal cell carcinoma. Two other Phase 1/2 combination studies are enrolling.
Glembatumumab vedotin (CDX-011) Phase 2 studies continued to enroll patients for metastatic triple negative breast cancer overexpressing gpNMB, but there is competition for patients, so behind on the timeline and opening sites in the EU to compensate.
CDX-011 for metastatic melanoma (post checkpoint therapy)
A CDX-011 Phase 1 study in squamous cell lung cancer
CDX-011 is also in NCI sponsored studies for uveal melanoma and pediatric osteosarcoma.
CDX-301 is in several early studies, one for HSCT (hematopoeitic stem cell transplantation) and one for B-cell lymphomas.
The combination of CDX-1401 and CDX-301 for malignant melanoma
CDX-014 started a Phase 1 study last July in renal cell carcinoma.
Cash ended at $
Operating expenses of $ million consisted of: $ million for R&D; $ million for general and administrative; and $ million amortization. There was $ million other revenue.
Q&A:
OpenIcon Analyst Conference Summaries Main Page
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| ALXN |
| AMAT |
| AMD |
| AMGN |
| BIIB |
| CLDX |
| CELG |
| EPZM |
| GILD |
| GLYC |
| INO |
| INTC |
| ISRG |
| JUNO |
| MACK |
| MCHP |
| MYL. |
| NVDA |
| PLX |
| REGN |
| SGEN |
| XLNX |
| XLRN |
Disclaimer: My analyst call summaries may include both our condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. This is investment journalism, not financial advice.
Copyright 2017 William P. Meyers